Table 1.
Demographics of Hepatocellular Carcinoma Patients Treated by Orthotopic Liver Transplantation.
| Variable | Hepatocellular carcinoma patients treated with orthotopic liver transplantation, (N=384) |
|---|---|
| Age, y, mean ± SD | 57.8±7.9 |
| Male sex, n (%) | 306 (79.7) |
| Race, n (%) | |
| Caucasian | 315 (82.0) |
| African American | 38 (9.9) |
| Other | 31 (8.1) |
| Etiology, n (%) | |
| Hepatitis C | 245 (63.8) |
| Alcoholic | 36 (9.4) |
| Nonalcoholic steatohepatitis | 56 (14.6) |
| Hepatitis B | 23 (6.0) |
| Other | 24 (6.2) |
| BMI, kg/m2, mean ± SD | 28.5±5.1 |
| Alpha-fetoprotein before orthotopic liver transplantation,ng/mL, mean ± SD | 101.1±539.1 |
| Neoadjuvant locoregionaltherapy, n (%) | |
| Transarterial chemoembolization | 254 (66.1) |
| Radiofrequency ablation | 9 (2.3) |
| Y90 | 4 (1.0) |
| Palmitoylethanolamide | 1 (0.3) |
| Non-neoadjuvant locoregionaltherapy | 116 (30.3) |
| MELD score | 15.6±8.3 |
| Explanted tumors | |
| No. of tumors, mean ± SD | 1.9±1.4 |
| Nodule size, cm, mean ± SD | 2.4±1.5 |
| Milan criteria within, n (%) | 353 (91.9) |
| Macrovascular invasion, n (%) | 16 (4.2) |
| Differentiation, n (%) | |
| Not applicable | 99 (25.8) |
| Well | 107 (27.9) |
| Moderate | 150 (39.1) |
| Poor | 28 (7.3) |
| Microscopic lymphovascularspace invasion, n (%) | 49 (12.8) |
| Necrosis, n (%) | |
| Non-necrosis | 158 (41.1) |
| Partial necrosis | 155 (40.4) |
| Complete necrosis | 71 (18.5) |
MELD, Model for End-Stage Liver Disease.